Immunologic Basis for Broad Protection against Enteric Fever Salmonella

广泛预防肠热沙门氏菌的免疫学基础

基本信息

项目摘要

Infections with Salmonella enterica serovar Typhi (S. Typhi), S. Paratyphi A and S. Paratyphi B are responsible for the vast majority of enteric fevers globally and are a major public health concern. Additionally, Salmonella spp are category B pathogens that have the potential to be used as bio-terror weapons. The overall goal of this application is to advance the development of cross-protective vaccines against enteric fevers by identifying humoral and cell-mediated immune responses (CMI) which might play significant roles in protection. A secondary overall aim is to provide data to validate the S. Typhi /S. Paratyphi A bivalent vaccine approach to vaccination against enteric fevers. The proposed studies will take advantage of peripheral blood mononuclear cells and sera specimens obtained from subjects orally immunized with Ty21a and CVD 909 typhoid vaccines or with the attenuated CVD 1902 S. Paratyphi A candidate vaccine, from subjects challenged with wild-type (wt)-S. Typhi and wt-S. Paratyphi A and from typhoid and paratyphoid A patients in endemic areas. We will utilize the power of cutting edge immunologic platforms such as mass and conventional multichromatic flow cytometry analysis and sorting to characterize S. Typhi-, S. Paratyphi A-, and B-specific B([memory]) (BM), T [memory] ¿, and T [regulatory] (T reg) responses, including their patterns of cytokine production and homing/chemokine receptor expression using a systems biology like approach. We will also perform immunoprofiling studies to identify genome-wide cross-reactive proteins that elicit serum antibody responses. Specifically, we propose to test the following hypotheses: (1) a defined set of CMI responses play a key role in cross-protection between S. Typhi and S. Paratyphi B infection in Ty21a-immunized subjects, (2) oral immunization of volunteers with an attenuated S. Paratyphi A vaccine strain (CVD 1902) or exposed to wt-S. Paratyphi A elicits a defined set of CMI responses against S. Paratyphi A antigens and infected cells that cross-react with S. Typhi and S. Paratyphi B antigens, and (3) oral immunization with the attenuated S. Paratyphi A CVD 1902 vaccine or exposure to wt-S. Paratyphi A (either in challenge studies or in endemic areas) elicits serum antibodies and BM, Beffector, and Breguiatory cells specific to S. Paratyphi A, as well as against Salmonella common antigens present in S. Typhi and S. Paratyphi B. These studies will contribute to the overall theme of this CETR application by providing novel and unique insights in humans that have the potential to advance the development of vaccine strategies to enteric fevers as well as other emerging enteric infections.
伤寒沙门氏菌、甲型副伤寒沙门氏菌和乙型副伤寒沙门氏菌的感染是全球绝大多数肠道发烧的原因,是一个主要的公共卫生问题。此外,沙门氏菌是B类病原体,有可能被用作生物恐怖武器。这项应用的总体目标是通过识别可能在保护中发挥重要作用的体液和细胞介导的免疫反应(CMI)来推动针对肠道发热的交叉保护性疫苗的开发。第二个总体目标是提供数据,以验证伤寒/副伤寒双价疫苗接种肠热病疫苗的方法。拟议的研究将利用从口服Ty21a和CVD909伤寒疫苗或减毒CVD1902S.Paratyphi A候选疫苗的受试者的外周血单核细胞和血清样本,以及来自野生型(Wt)-S挑战的受试者。伤寒和Wt-S。甲型副伤寒和流行地区的伤寒和甲型副伤寒患者。我们将利用尖端免疫学平台的力量,如质量和传统的多色流式细胞术分析和分类来表征伤寒沙门氏菌、副伤寒沙门氏菌A-和B-特异性B([Memory])(BM)、T[Memory]和T[调节性](T Reg)反应,包括 他们的细胞因子产生和归巢/趋化因子受体表达的模式使用类似系统生物学的方法。我们还将进行免疫图谱研究,以确定能引起血清抗体反应的全基因组交叉反应蛋白。具体地说,我们建议检验以下假设: (1)一组明确的CMI反应在Ty21a免疫受试者中伤寒沙门氏菌和副伤寒沙门氏菌B感染之间的交叉保护中发挥关键作用;(2)志愿者口服甲型副伤寒沙门氏菌减毒疫苗株(CVD 1902)或暴露在wt-S中。甲型副伤寒引起针对甲型副伤寒沙门氏菌抗原和与甲型副伤寒沙门氏菌和乙型副伤寒沙门氏菌交叉反应的感染细胞的一组明确的CMI反应,以及(3)口服甲型副伤寒沙门氏菌CVD 1902疫苗或暴露于wt-S。甲型副伤寒沙门氏菌(无论是在挑战研究中还是在流行地区)引起针对甲型副伤寒沙门氏菌和乙型副伤寒沙门氏菌共同抗原的血清抗体和BM、BEffector和Breguiating细胞。这些研究将通过在人类中提供新颖和独特的见解来促进针对肠道发烧和其他新出现的肠道感染的疫苗策略的开发,从而为CETR应用的总体主题做出贡献。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Marcelo B. Sztein其他文献

Thymic physiology and biochemistry.
胸腺生理学和生物化学。
  • DOI:
  • 发表时间:
    1987
  • 期刊:
  • 影响因子:
    0
  • 作者:
    R. Schulof;Paul H. Naylor;Marcelo B. Sztein;Allan L. Goldstein
  • 通讯作者:
    Allan L. Goldstein
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road
志贺菌疫苗的临床试验:在漫长而艰难的道路上前进两步后退一步
  • DOI:
    10.1038/nrmicro1662
  • 发表时间:
    2007-07-01
  • 期刊:
  • 影响因子:
    103.300
  • 作者:
    Myron M. Levine;Karen L. Kotloff;Eileen M. Barry;Marcela F. Pasetti;Marcelo B. Sztein
  • 通讯作者:
    Marcelo B. Sztein
The two-faced T cell epitope
双面T细胞表位
  • DOI:
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    L. Moise;Andres H. Gutierrez;C. Bailey;Frances E Terry;Qibin Leng;Karim M. Abdel Hady;Nathan c. VerBerkmoes;Marcelo B. Sztein;P. Losikoff;William D. Martin;Alan Rothman;Anne Searls De Groot
  • 通讯作者:
    Anne Searls De Groot
Tu1886 – Commensal Derived Bioproducts Contribute to Modulate <em>S.</em> Typhi-Host Interaction
  • DOI:
    10.1016/s0016-5085(19)39869-5
  • 发表时间:
    2019-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Stefania Senger;Laura Ingano;Kourtney Nickerson;Marcelo B. Sztein;Alessio Fasano
  • 通讯作者:
    Alessio Fasano
Safety and immunogenicity in humans of enterotoxigenic Escherichia coli double mutant heat-labile toxin administered intradermally
皮内注射产肠毒素大肠埃希氏菌双突变不耐热肠毒素在人体中的安全性和免疫原性
  • DOI:
    10.1038/s41541-025-01071-7
  • 发表时间:
    2025-02-01
  • 期刊:
  • 影响因子:
    6.500
  • 作者:
    Marcela F. Pasetti;Patricia L. Milletich;Jessica A. White;Jessica Butts;Rebecca C. Brady;Michelle D. Dickey;Cassandra Ballou;Nicole Maier;Marcelo B. Sztein;Shahida Baqar;A. Louis Bourgeois;David I. Bernstein
  • 通讯作者:
    David I. Bernstein

Marcelo B. Sztein的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Marcelo B. Sztein', 18)}}的其他基金

Defining immunological mechanisms of serovar cross-reactivity to develop broad spectrum protective vaccines for typhoidal and non-typhoidal Salmonella infections in humans
定义血清型交叉反应的免疫学机制,以开发针对人类伤寒和非伤寒沙门氏菌感染的广谱保护性疫苗
  • 批准号:
    10584484
  • 财政年份:
    2019
  • 资助金额:
    $ 75.66万
  • 项目类别:
Defining immunological mechanisms of serovar cross-reactivity to develop broad spectrum protective vaccines for typhoidal and non-typhoidal Salmonella infections in humans
定义血清型交叉反应的免疫学机制,以开发针对人类伤寒和非伤寒沙门氏菌感染的广谱保护性疫苗
  • 批准号:
    10364714
  • 财政年份:
    2019
  • 资助金额:
    $ 75.66万
  • 项目类别:
Broad spectrum vaccines to enteric fevers in humans: cross protective immunity
人类肠热病广谱疫苗:交叉保护性免疫
  • 批准号:
    8233359
  • 财政年份:
    2011
  • 资助金额:
    $ 75.66万
  • 项目类别:
Mucosal Immunity, Vaccines and Microbiota Interplay in Humans and Animal
人类和动物的粘膜免疫、疫苗和微生物群的相互作用
  • 批准号:
    8282922
  • 财政年份:
    2009
  • 资助金额:
    $ 75.66万
  • 项目类别:
Mucusal and Systemic Immunity, Vaccines and Microbiota Interplay in Humans
人类粘膜和系统免疫、疫苗和微生物群的相互作用
  • 批准号:
    8835015
  • 财政年份:
    2009
  • 资助金额:
    $ 75.66万
  • 项目类别:
Mucusal and Systemic Immunity, Vaccines and Microbiota Interplay in Humans
人类粘膜和系统免疫、疫苗和微生物群的相互作用
  • 批准号:
    8707660
  • 财政年份:
    2009
  • 资助金额:
    $ 75.66万
  • 项目类别:
Mucosal Immunity, Vaccines and Microbiota Interplay in Humans and Animal
人类和动物的粘膜免疫、疫苗和微生物群的相互作用
  • 批准号:
    8119519
  • 财政年份:
    2009
  • 资助金额:
    $ 75.66万
  • 项目类别:
Mucosal Immunity, Vaccines and Microbiota Interplay in Humans and Animal
人类和动物的粘膜免疫、疫苗和微生物群的相互作用
  • 批准号:
    8485521
  • 财政年份:
    2009
  • 资助金额:
    $ 75.66万
  • 项目类别:
Pilot Projects Research Core
试点项目研究核心
  • 批准号:
    7701569
  • 财政年份:
    2009
  • 资助金额:
    $ 75.66万
  • 项目类别:
A novel whole ORFeome approach to identify CD8+ T cell responses to S. Typhi prot
一种新颖的全 ORFeome 方法来识别 CD8 T 细胞对伤寒沙门氏菌 prot 的反应
  • 批准号:
    7701566
  • 财政年份:
    2009
  • 资助金额:
    $ 75.66万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 75.66万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 75.66万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 75.66万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 75.66万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 75.66万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 75.66万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 75.66万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 75.66万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 75.66万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 75.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了